FIIs Pour ₹8,250 Crore into Indian Equities; Biggest Buy Since March 27, 2025

Foreign institutional investors (FIIs) continued their bullish momentum for the eighth straight session on Thursday, April 24, infusing a massive ₹8,250 crore into Indian equities—their largest single-day purchase since March 27.

In contrast, domestic institutional investors (DIIs) took the opportunity to book profits, offloading equities worth ₹534 crore.

FIIs Outbuy DIIs Despite Being 2024 Net Sellers

During Thursday’s session, FIIs bought shares worth ₹24,089 crore while selling stocks valued at ₹15,838 crore. Meanwhile, DIIs purchased ₹13,452 crore worth of shares and sold ₹13,986 crore.

Despite the recent inflows, FIIs remain net sellers in 2024 to the tune of ₹1.45 lakh crore, while DIIs have net purchased ₹1.97 lakh crore, highlighting their supportive role in keeping the markets resilient over the year.

Markets Snap 7-Day Rally on Expiry Day

The broader market sentiment took a hit as benchmark indices Nifty 50 and Sensex ended their seven-session winning streak, dragged down by a volatile expiry-day session and weak earnings from FMCG majors.

The FMCG index emerged as the worst performer, slipping over 1% after disappointing Q4 results from Hindustan Unilever Ltd. (HUL), Nestle India, and Tata Consumer Products.

Pharma Gains as Broader Markets Turn Cautious

In contrast, the Nifty Pharma index defied the trend, rising nearly 1%, supported by robust gains in Natco Pharma, Divi’s Laboratories, and Ajanta Pharma, with individual stocks rallying up to 12%.

Other key sectoral indices—Nifty Auto, Bank, IT, and Realty—also closed in the red, slipping between 0.4% and 1.4%.

The broader markets mirrored the cautious tone, with the Nifty Midcap 100 dipping 0.2%, and the Nifty Smallcap 100 closing marginally lower, giving up some gains after a strong rally in prior sessions.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.